We bring you the latest news from the healthcare about the health care in the United Kingdom.

donderdag 4 januari 2018

The Lancet: [Articles] Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients ...

[Articles] Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial
Extended-pulsed fidaxomicin was superior to standard-dose vancomycin for sustained cure of C difficile infection, and, to our knowledge, extended-pulsed fidaxomicin recurrence rates in this study are the lowest observed in a randomised clinical trial of antibiotic treatment for C difficile infection.
Read more

[Articles] Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis
Future development strategies should focus on antibiotics that are active against multidrug-resistant tuberculosis and Gram-negative bacteria. The global strategy should include antibiotic-resistant bacteria responsible for community-acquired infections such as Salmonella spp, Campylobacter spp, N gonorrhoeae, and H pylori.
Read more

[Correspondence] Dengvaxia: age as surrogate for serostatus
Since April, 2016, Dengvaxia—a dengue vaccine produced by Sanofi Pasteur (Lyon, France)—has been licensed for use in 19 countries. Dengvaxia was recommended by the WHO Strategic Advisory Group of Experts (SAGE) on immunisation to be used in regions with high endemicity, as defined by a prevalence of dengue antibodies of more than 50% in the targeted age group of people aged 9–45 years.1 We have previously discussed the risks behind this vaccine recommendation,2,3 and by analysing an age-structured model4 using the available vaccine trial data1 predicted a significant reduction in dengue virus infection-related hospital admissions if Dengvaxia is given only to individuals who are seropositive for dengue antibodies.
Read more

[Comment] A crucial list of pathogens
In this issue of The Lancet Infectious Diseases, Evelina Tacconelli and colleagues, and the WHO Pathogens Priority List Working Group,1 describe how WHO created a priority list of antibiotic-resistant bacteria to support research into and development of effective drugs. The authors used a multicriteria decision analysis method to prioritise antibiotic-resistant bacteria: 20 bacterial species with 25 patterns of acquired resistance and ten criteria to assess priority were used to generate the list.
Read more

[Corrections] Corrections
de Ara├║jo TVB, Ximenes RAA, Miranda-Filho DB, et al. Association between microcephaly, Zika virus infection, and other risk factors in Brazil: final report of a case-control study. Lancet Infect Dis 2017; published online Dec 11. http://dx.doi.org/10.1016/S1473-3099(17)30727-2—Celina Maria Turchi Martelli and Laura Cunha Rodrigues should have been listed as authors who contributed equally. This correction has been made to the online version as of January 4, 2018.
Read more